A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -7.06M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.